Hypofractionation for Prostate Cancer
- 1 January 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The Cancer Journal
- Vol. 15 (1), 1-6
- https://doi.org/10.1097/ppo.0b013e3181976614
Abstract
Hypofractionation for prostate cancer was originally carried out in the pursuit of efficiency and convenience but has now attracted greatly renewed interest based upon a hypothesis that prostate cancers have a higher sensitivity to fraction size, reflected in a low α/β ratio, than do late responding organs at risk such as the rectum or bladder. Tumor control and acceptable toxicity outcomes from several hypofractionation or brachytherapy analyses do in fact support an α/β ratio for prostate cancer that is low, perhaps even lower that that for the normal organs that ordinarily constrain the delivery of radiation therapy. However, many of these studies lack sufficient patient numbers and follow-up, are clouded by dose inhomogeneity issues in the case of brachytherapy, or delivered effective doses that were too low by contemporary standards. Thus, the clinical efficacy of the approach has yet to be fully validated. However, a number of newer prospective trials, some randomized, are underway or have reached accrual but await sufficient follow-up for analysis. These studies, which cover a wide range of doses per fraction, should ultimately be capable of validating the utility of prostate hypofractionation and the models that predict its effects. With hypofractionation's significant potential for therapeutic gain, cost savings, and improved patient convenience, the future management of localized prostate cancer could be profoundly altered in the process.Keywords
This publication has 42 references indexed in Scilit:
- Phase I/II Study of a Five-fraction Hypofractionated Accelerated Radiotherapy Treatment for Low-risk Localised Prostate Cancer: Early Results of pHART3Clinical Oncology, 2008
- Question of Dose, Fractionation and Technique: Ingredients for Testing Hypofractionation in Prostate Cancer – the CHHiP TrialClinical Oncology, 2008
- Is the α/β Value for Prostate Tumours Low Enough to be Safely Used in Clinical Trials?Clinical Oncology, 2007
- Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: Report on acute toxicityRadiotherapy and Oncology, 2006
- Hypofractionated radiotherapy with carbon ion beams for prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate CancerJournal of Clinical Oncology, 2005
- Carcinoma of the prostate: Results of radical radiotherapy (1970–1985)International Journal of Radiation Oncology*Biology*Physics, 1993
- The radiobiology of radiosurgery: Rationale for different treatment regimes for AVMs and malignanciesInternational Journal of Radiation Oncology*Biology*Physics, 1993
- Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation techniqueClinical Oncology, 1991
- Retrospective Study of Radiotherapy in Early Carcinoma of the ProstateBritish Journal of Urology, 1989